Rebeccamycin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Rebeccamycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
Line 16: Line 16:
}}
}}
{{SI}}
{{SI}}
{{EH}}
 


==Overview==
==Overview==
Line 29: Line 29:
</div>
</div>


{{SIB}}
 
[[Category:Chemotherapeutic agents]]
[[Category:Chemotherapeutic agents]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 15:34, 20 August 2012

Rebeccamycin
File:Rebeccamycin.png
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H21Cl2N3O7
Molar mass570.38

WikiDoc Resources for Rebeccamycin

Articles

Most recent articles on Rebeccamycin

Most cited articles on Rebeccamycin

Review articles on Rebeccamycin

Articles on Rebeccamycin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Rebeccamycin

Images of Rebeccamycin

Photos of Rebeccamycin

Podcasts & MP3s on Rebeccamycin

Videos on Rebeccamycin

Evidence Based Medicine

Cochrane Collaboration on Rebeccamycin

Bandolier on Rebeccamycin

TRIP on Rebeccamycin

Clinical Trials

Ongoing Trials on Rebeccamycin at Clinical Trials.gov

Trial results on Rebeccamycin

Clinical Trials on Rebeccamycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Rebeccamycin

NICE Guidance on Rebeccamycin

NHS PRODIGY Guidance

FDA on Rebeccamycin

CDC on Rebeccamycin

Books

Books on Rebeccamycin

News

Rebeccamycin in the news

Be alerted to news on Rebeccamycin

News trends on Rebeccamycin

Commentary

Blogs on Rebeccamycin

Definitions

Definitions of Rebeccamycin

Patient Resources / Community

Patient resources on Rebeccamycin

Discussion groups on Rebeccamycin

Patient Handouts on Rebeccamycin

Directions to Hospitals Treating Rebeccamycin

Risk calculators and risk factors for Rebeccamycin

Healthcare Provider Resources

Symptoms of Rebeccamycin

Causes & Risk Factors for Rebeccamycin

Diagnostic studies for Rebeccamycin

Treatment of Rebeccamycin

Continuing Medical Education (CME)

CME Programs on Rebeccamycin

International

Rebeccamycin en Espanol

Rebeccamycin en Francais

Business

Rebeccamycin in the Marketplace

Patents on Rebeccamycin

Experimental / Informatics

List of terms related to Rebeccamycin


Overview

Rebeccamycin is a weak topoisomerase I inhibitor isolated from Streptomyces sp. structurally similar to staurosporine. Does not show any inhibitory activity against protein kinases. Shows significant antitumor properties in vitro (IC50=480nM against mouse B16 melanoma cells and IC50=500nM against P388 leukemia cells).

References

  • Production and biological activity of rebeccamycin, a novel antitumor agent: J.A. Bush, et al.; J. Antibiot. (Tokyo) 40, 668 (1987)
  • Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group F. Anizon, et al.; J. Med. Chem. 40, 3456 (1997)
  • DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin: C. Bailly, et al.; Biochemistry 36, 3917 (1997)
  • Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition: C. Bailly, et al.; Chem. Biol. 6, 277 (1999)

Template:WH Template:WS